Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination ophthalmic formulation** containing the following active ingredients: **n-acetylcarnosine**, **vaccinium myrtillus extract**, and **chondroitin sulfate**. - **N-acetylcarnosine** acts as a prodrug of carnosine, a water-soluble antioxidant, and is believed to exert protective effects in the eye by scavenging reactive oxygen species, preventing lipid peroxidation, and protecting lens proteins from oxidation, thus potentially delaying or improving age-related cataract development[3][5]. - **Vaccinium myrtillus extract** (bilberry extract) is rich in anthocyanins, which function as antioxidants and may help support retinal microcirculation and reduce oxidative stress. - **Chondroitin sulfate** is a glycosaminoglycan with lubricating and anti-inflammatory properties used to enhance ocular surface moisture, stabilize the tear film, and protect the corneal epithelium. This combination is marketed for ophthalmic use, primarily as **eye drops** for the prevention and management of cataracts, improvement of visual function, and protection against oxidative stress and inflammation in the eye[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-acetylcarnosine + vaccinium myrtillus + chondroitin sulfate.